Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Edgewise Therapeutics, Inc.

NASDAQ: EWTX · Life Sciences · 3 alerts · CIK 1710072

Share price
$43.68Close, Nov 16
Market cap
$4.78B
Shares outstanding
109.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Edgewise Therapeutics, Inc. filings on SEC EDGAR ↗

4:02 PM ET 8-K
Financial Results

Edgewise Therapeutics Financial Results

Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.

“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”

Kevin Koch, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.